Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports.

Other equities research analysts have also recently issued research reports about the company. Jefferies Financial Group cut their target price on Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Thursday, July 24th. Robert W. Baird lifted their price objective on Sarepta Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Morgan Stanley lifted their price objective on Sarepta Therapeutics from $15.00 to $20.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 29th. Wolfe Research assumed coverage on Sarepta Therapeutics in a report on Tuesday, June 17th. They issued a “peer perform” rating for the company. Finally, Leerink Partnrs lowered Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, July 18th. Eight analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have issued a Sell rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Hold” and a consensus target price of $43.50.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded up $0.27 during midday trading on Monday, hitting $18.34. The company had a trading volume of 5,495,896 shares, compared to its average volume of 6,276,187. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $140.10. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -21.08 and a beta of 0.46. The business’s 50-day simple moving average is $17.81 and its 200-day simple moving average is $48.74.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The firm had revenue of $611.09 million during the quarter, compared to analysts’ expectations of $530.66 million. During the same quarter last year, the firm earned $0.07 earnings per share. The business’s revenue for the quarter was up 68.4% on a year-over-year basis. On average, research analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently bought and sold shares of the business. EP Wealth Advisors LLC lifted its holdings in Sarepta Therapeutics by 2.2% during the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock worth $606,000 after buying an additional 105 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Sarepta Therapeutics by 4.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company’s stock worth $571,000 after buying an additional 218 shares during the last quarter. UMB Bank n.a. lifted its holdings in Sarepta Therapeutics by 53.0% during the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company’s stock worth $51,000 after buying an additional 276 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in Sarepta Therapeutics by 2.6% during the 1st quarter. State of Alaska Department of Revenue now owns 11,175 shares of the biotechnology company’s stock worth $713,000 after buying an additional 285 shares during the last quarter. Finally, State of Michigan Retirement System lifted its holdings in Sarepta Therapeutics by 1.3% during the 1st quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company’s stock worth $1,461,000 after buying an additional 300 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.